Abbott signs seven-year deal with Premier:
This article was originally published in Clinica
Abbott Laboratories has signed a seven-year "multi-billion" dollar contract with Premier, the Charlotte, North Carolina-based hospital purchasing group. The contract extends a previous agreement, which covered items such as imaging agents, and areas including critical care and immunochemistry. The new terms also include patient-controlled analgesia, haematology and anaesthesia trays.
You may also be interested in...
Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.